Pharmacokinetics of first-line tuberculosis drugs in Tanzanian patients

East Africa has a high tuberculosis (TB) incidence and mortality, yet there are very limited data on exposure to TB drugs in patients from this region. We therefore determined the pharmacokinetic characteristics of first-line TB drugs in Tanzanian patients using intensive pharmacokinetic sampling. I...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	Antimicrobial agents and chemotherapy Ročník 57; číslo 7; s. 3208
Hlavní autori:	Tostmann, Alma, Mtabho, Charles M, Semvua, Hadija H, van den Boogaard, Jossy, Kibiki, Gibson S, Boeree, Martin J, Aarnoutse, Rob E
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	United States 01.07.2013
Predmet:	Adult Antitubercular Agents - blood Antitubercular Agents - pharmacokinetics Antitubercular Agents - therapeutic use Ethambutol - blood Ethambutol - pharmacokinetics Ethambutol - therapeutic use Female Humans Isoniazid - blood Isoniazid - pharmacokinetics Isoniazid - therapeutic use Male Pyrazinamide - blood Pyrazinamide - pharmacokinetics Pyrazinamide - therapeutic use Rifampin - blood Rifampin - pharmacokinetics Rifampin - therapeutic use Tanzania Treatment Outcome Tuberculosis, Pulmonary - drug therapy Tanzania
ISSN:	1098-6596, 1098-6596
On-line prístup:	Zistit podrobnosti o prístupe
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Abstract	East Africa has a high tuberculosis (TB) incidence and mortality, yet there are very limited data on exposure to TB drugs in patients from this region. We therefore determined the pharmacokinetic characteristics of first-line TB drugs in Tanzanian patients using intensive pharmacokinetic sampling. In 20 adult TB patients, plasma concentrations were determined just before and at 1, 2, 3, 4, 6, 8, 10, and 24 h after observed drug intake with food to estimate the areas under the curve from 0 to 24 h (AUC0-24) and peak plasma concentrations (Cmax) of isoniazid, rifampin, pyrazinamide, and ethambutol. Acetylator status for isoniazid was assessed phenotypically using the isoniazid elimination half-life and the acetylisoniazid/isoniazid metabolic ratio at 3 h postdose. The geometric mean AUC0-24s were as follows: isoniazid, 11.0 h · mg/liter; rifampin, 39.9 h · mg/liter; pyrazinamide, 344 h · mg/liter; and ethambutol, 20.2 h · mg/liter. The Cmax was below the reference range for isoniazid in 10/19 patients and for rifampin in 7/20 patients. In none of the patients were the Cmaxs for pyrazinamide and ethambutol below the reference range. Elimination half-life and metabolic ratio of isoniazid gave discordant phenotyping results in only 2/19 patients. A substantial proportion of patients had an isoniazid and/or rifampin Cmax below the reference range. Intake of TB drugs with food may partly explain these low drug levels, but such a drug intake reflects common practice. The finding of low TB drug concentrations is concerning because low concentrations have been associated with worse treatment outcome in several other studies.
AbstractList	East Africa has a high tuberculosis (TB) incidence and mortality, yet there are very limited data on exposure to TB drugs in patients from this region. We therefore determined the pharmacokinetic characteristics of first-line TB drugs in Tanzanian patients using intensive pharmacokinetic sampling. In 20 adult TB patients, plasma concentrations were determined just before and at 1, 2, 3, 4, 6, 8, 10, and 24 h after observed drug intake with food to estimate the areas under the curve from 0 to 24 h (AUC0-24) and peak plasma concentrations (Cmax) of isoniazid, rifampin, pyrazinamide, and ethambutol. Acetylator status for isoniazid was assessed phenotypically using the isoniazid elimination half-life and the acetylisoniazid/isoniazid metabolic ratio at 3 h postdose. The geometric mean AUC0-24s were as follows: isoniazid, 11.0 h · mg/liter; rifampin, 39.9 h · mg/liter; pyrazinamide, 344 h · mg/liter; and ethambutol, 20.2 h · mg/liter. The Cmax was below the reference range for isoniazid in 10/19 patients and for rifampin in 7/20 patients. In none of the patients were the Cmaxs for pyrazinamide and ethambutol below the reference range. Elimination half-life and metabolic ratio of isoniazid gave discordant phenotyping results in only 2/19 patients. A substantial proportion of patients had an isoniazid and/or rifampin Cmax below the reference range. Intake of TB drugs with food may partly explain these low drug levels, but such a drug intake reflects common practice. The finding of low TB drug concentrations is concerning because low concentrations have been associated with worse treatment outcome in several other studies.East Africa has a high tuberculosis (TB) incidence and mortality, yet there are very limited data on exposure to TB drugs in patients from this region. We therefore determined the pharmacokinetic characteristics of first-line TB drugs in Tanzanian patients using intensive pharmacokinetic sampling. In 20 adult TB patients, plasma concentrations were determined just before and at 1, 2, 3, 4, 6, 8, 10, and 24 h after observed drug intake with food to estimate the areas under the curve from 0 to 24 h (AUC0-24) and peak plasma concentrations (Cmax) of isoniazid, rifampin, pyrazinamide, and ethambutol. Acetylator status for isoniazid was assessed phenotypically using the isoniazid elimination half-life and the acetylisoniazid/isoniazid metabolic ratio at 3 h postdose. The geometric mean AUC0-24s were as follows: isoniazid, 11.0 h · mg/liter; rifampin, 39.9 h · mg/liter; pyrazinamide, 344 h · mg/liter; and ethambutol, 20.2 h · mg/liter. The Cmax was below the reference range for isoniazid in 10/19 patients and for rifampin in 7/20 patients. In none of the patients were the Cmaxs for pyrazinamide and ethambutol below the reference range. Elimination half-life and metabolic ratio of isoniazid gave discordant phenotyping results in only 2/19 patients. A substantial proportion of patients had an isoniazid and/or rifampin Cmax below the reference range. Intake of TB drugs with food may partly explain these low drug levels, but such a drug intake reflects common practice. The finding of low TB drug concentrations is concerning because low concentrations have been associated with worse treatment outcome in several other studies. East Africa has a high tuberculosis (TB) incidence and mortality, yet there are very limited data on exposure to TB drugs in patients from this region. We therefore determined the pharmacokinetic characteristics of first-line TB drugs in Tanzanian patients using intensive pharmacokinetic sampling. In 20 adult TB patients, plasma concentrations were determined just before and at 1, 2, 3, 4, 6, 8, 10, and 24 h after observed drug intake with food to estimate the areas under the curve from 0 to 24 h (AUC0-24) and peak plasma concentrations (Cmax) of isoniazid, rifampin, pyrazinamide, and ethambutol. Acetylator status for isoniazid was assessed phenotypically using the isoniazid elimination half-life and the acetylisoniazid/isoniazid metabolic ratio at 3 h postdose. The geometric mean AUC0-24s were as follows: isoniazid, 11.0 h · mg/liter; rifampin, 39.9 h · mg/liter; pyrazinamide, 344 h · mg/liter; and ethambutol, 20.2 h · mg/liter. The Cmax was below the reference range for isoniazid in 10/19 patients and for rifampin in 7/20 patients. In none of the patients were the Cmaxs for pyrazinamide and ethambutol below the reference range. Elimination half-life and metabolic ratio of isoniazid gave discordant phenotyping results in only 2/19 patients. A substantial proportion of patients had an isoniazid and/or rifampin Cmax below the reference range. Intake of TB drugs with food may partly explain these low drug levels, but such a drug intake reflects common practice. The finding of low TB drug concentrations is concerning because low concentrations have been associated with worse treatment outcome in several other studies.
Author	Kibiki, Gibson S Aarnoutse, Rob E Boeree, Martin J Mtabho, Charles M Semvua, Hadija H Tostmann, Alma van den Boogaard, Jossy
Author_xml	– sequence: 1 givenname: Alma surname: Tostmann fullname: Tostmann, Alma email: A.Tostmann@elg.umcn.nl organization: Department of Respiratory Diseases, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands. A.Tostmann@elg.umcn.nl – sequence: 2 givenname: Charles M surname: Mtabho fullname: Mtabho, Charles M – sequence: 3 givenname: Hadija H surname: Semvua fullname: Semvua, Hadija H – sequence: 4 givenname: Jossy surname: van den Boogaard fullname: van den Boogaard, Jossy – sequence: 5 givenname: Gibson S surname: Kibiki fullname: Kibiki, Gibson S – sequence: 6 givenname: Martin J surname: Boeree fullname: Boeree, Martin J – sequence: 7 givenname: Rob E surname: Aarnoutse fullname: Aarnoutse, Rob E
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/23629715$$D View this record in MEDLINE/PubMed
BookMark	eNpNj81LwzAYxoNM3IfePEuOXjqTtEma4xhuCgM9zHPJx1uNtulM0oP-9Q6c4On54McDzxxNwhAAoWtKlpSy-m61Wi8J40oVlJ2hGSWqLgRXYvLPT9E8pXdCyDGQCzRlpWBKUj5D2-c3HXtthw8fIHub8NDi1seUi-7Y4DwaiHbshuQTdnF8TdgHvNfhWwevAz7o7CHkdInOW90luDrpAr1s7vfrh2L3tH1cr3aF5kTmgmtHtVZEgeK1rStqJKeidZU0lSytqUoAZZ0zouUlSMOYk4xzWcraECEUW6Db391DHD5HSLnpfbLQdTrAMKaGlkLWUlLFj-jNCR1ND645RN_r-NX8nWc_F79dDg
CitedBy_id	crossref_primary_10_1002_cpt_646 crossref_primary_10_1177_0960327121997975 crossref_primary_10_3390_antibiotics10121559 crossref_primary_10_1128_aac_00737_23 crossref_primary_10_1128_AAC_02586_15 crossref_primary_10_1111_bcp_14207 crossref_primary_10_1093_jac_dku348 crossref_primary_10_1111_bcp_14522 crossref_primary_10_1111_cts_13520 crossref_primary_10_1002_phar_1730 crossref_primary_10_1093_jac_dky444 crossref_primary_10_1016_j_tube_2023_102367 crossref_primary_10_1111_apm_12590 crossref_primary_10_1128_AAC_02379_13 crossref_primary_10_1093_chromsci_bmaa130 crossref_primary_10_1097_FTD_0000000000000093 crossref_primary_10_1038_s41598_017_00529_6 crossref_primary_10_1002_jssc_202000672 crossref_primary_10_1128_AAC_01193_15 crossref_primary_10_2147_IDR_S513294 crossref_primary_10_1016_j_clinthera_2020_09_009 crossref_primary_10_1016_j_ijantimicag_2014_04_019 crossref_primary_10_1007_s10620_020_06121_9 crossref_primary_10_1007_s40262_014_0170_1 crossref_primary_10_1128_aac_00099_25 crossref_primary_10_1128_AAC_00693_15 crossref_primary_10_1093_femsre_fuaa071 crossref_primary_10_1128_AAC_00480_16 crossref_primary_10_4081_monaldi_2024_3036 crossref_primary_10_2196_58720 crossref_primary_10_1007_s13318_020_00657_x crossref_primary_10_1002_cpdd_465 crossref_primary_10_2217_pgs_2018_0166 crossref_primary_10_1016_j_actatropica_2022_106776 crossref_primary_10_1002_psp4_12079 crossref_primary_10_3390_antibiotics13121216 crossref_primary_10_1073_pnas_2417525122 crossref_primary_10_1128_AAC_01054_17 crossref_primary_10_1183_13993003_00986_2016 crossref_primary_10_1111_bcp_12848 crossref_primary_10_1128_AAC_01978_19 crossref_primary_10_1080_23744235_2024_2309348 crossref_primary_10_1371_journal_pcbi_1005321 crossref_primary_10_1371_journal_pone_0141002 crossref_primary_10_1128_AAC_02464_16 crossref_primary_10_1002_bmc_4812 crossref_primary_10_1007_s40262_020_00971_2 crossref_primary_10_3389_fcimb_2022_933458
ContentType	Journal Article
DBID	CGR CUY CVF ECM EIF NPM 7X8
DOI	10.1128/AAC.02599-12
DatabaseName	Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic
DatabaseTitle	MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic
DatabaseTitleList	MEDLINE - Academic MEDLINE
Database_xml	– sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database
DeliveryMethod	no_fulltext_linktorsrc
Discipline	Medicine Biology Pharmacy, Therapeutics, & Pharmacology
EISSN	1098-6596
ExternalDocumentID	23629715
Genre	Research Support, Non-U.S. Gov't Journal Article
GeographicLocations	Tanzania
GeographicLocations_xml	– name: Tanzania
GroupedDBID	--- .55 .GJ 0R~ 23M 2WC 39C 3O- 4.4 53G 5GY 5RE 5VS 6J9 ACGFO ADBBV AENEX AGNAY AGVNZ AI. ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL BTFSW C1A CGR CS3 CUY CVF DIK E3Z EBS ECM EIF EJD F5P FRP GX1 H13 HH5 HYE HZ~ H~9 J5H K-O KQ8 L7B LSO MVM NEJ NPM O9- OK1 P2P RHI RNS RPM RSF TR2 UHB VH1 W2D W8F WH7 WHG WOQ X7M X7N XOL Y6R ZGI ZXP ~A~ 7X8 AAGFI
ID	FETCH-LOGICAL-a507t-5ad1aa909e958c841b7516fd47b473cb43ee9cddb6f53e7b22d72557378b06692
IEDL.DBID	7X8
ISICitedReferencesCount	55
ISICitedReferencesURI	http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000320229600038&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN	1098-6596
IngestDate	Fri Sep 05 08:27:45 EDT 2025 Thu Apr 03 07:09:38 EDT 2025
IsDoiOpenAccess	false
IsOpenAccess	true
IsPeerReviewed	true
IsScholarly	true
Issue	7
Language	English
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-a507t-5ad1aa909e958c841b7516fd47b473cb43ee9cddb6f53e7b22d72557378b06692
Notes	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
OpenAccessLink	https://aac.asm.org/content/aac/57/7/3208.full.pdf
PMID	23629715
PQID	1367877195
PQPubID	23479
ParticipantIDs	proquest_miscellaneous_1367877195 pubmed_primary_23629715
PublicationCentury	2000
PublicationDate	2013-07-01
PublicationDateYYYYMMDD	2013-07-01
PublicationDate_xml	– month: 07 year: 2013 text: 2013-07-01 day: 01
PublicationDecade	2010
PublicationPlace	United States
PublicationPlace_xml	– name: United States
PublicationTitle	Antimicrobial agents and chemotherapy
PublicationTitleAlternate	Antimicrob Agents Chemother
PublicationYear	2013
References	6721995 - Br J Clin Pharmacol. 1984 Apr;17(4):481-4 22467672 - Clin Infect Dis. 2012 Jul;55(2):178-9 9154882 - Am J Respir Crit Care Med. 1997 May;155(5):1717-22 14699462 - Clin Infect Dis. 2004 Jan 15;38(2):280-3 19432554 - Clin Infect Dis. 2009 Jun 15;48(12):1685-94 9855317 - Pharmacotherapy. 1998 Nov-Dec;18(6):1205-11 12381217 - Drugs. 2002;62(15):2169-83 3768246 - Br J Clin Pharmacol. 1986 Sep;22(3):343-5 17452486 - Antimicrob Agents Chemother. 2007 Jul;51(7):2546-51 20550762 - Int J Tuberc Lung Dis. 2010 Jul;14(7):806-18 9243044 - Clin Infect Dis. 1997 Jul;25(1):104-11 1938852 - J Assoc Physicians India. 1991 Jun;39(6):470-1 18214560 - Eur J Clin Microbiol Infect Dis. 2008 Jun;27(6):467-72 11713129 - Chest. 2001 Nov;120(5):1520-4 12531776 - Am J Respir Crit Care Med. 2003 May 15;167(10):1341-7 9265429 - Ann Intern Med. 1997 Aug 15;127(4):289-93 6385429 - Tubercle. 1984 Sep;65(3):211-27 6391781 - Clin Pharmacokinet. 1984 Nov-Dec;9(6):511-44 9596291 - Chest. 1998 May;113(5):1178-83 16028152 - Clin Infect Dis. 2005 Aug 15;41(4):461-9 11170964 - Clin Infect Dis. 2001 Feb 1;32(3):515-7 11499851 - Pharmacoepidemiol Drug Saf. 2001 Mar-Apr;10(2):127-34 10460103 - Int J Tuberc Lung Dis. 1999 Aug;3(8):703-10 15844071 - Clin Infect Dis. 2005 May 15;40(10):1481-91 16569826 - Antimicrob Agents Chemother. 2006 Apr;50(4):1170-7 22467670 - Clin Infect Dis. 2012 Jul;55(2):169-77 7780091 - Tuber Lung Dis. 1995 Apr;76(2):109-13 10049268 - Antimicrob Agents Chemother. 1999 Mar;43(3):568-72 19947806 - Pharmacotherapy. 2009 Dec;29(12):1468-81 9925057 - Chest. 1999 Jan;115(1):12-8 22021624 - J Infect Dis. 2011 Dec 15;204(12):1951-9
References_xml	– reference: 15844071 - Clin Infect Dis. 2005 May 15;40(10):1481-91 – reference: 22021624 - J Infect Dis. 2011 Dec 15;204(12):1951-9 – reference: 9855317 - Pharmacotherapy. 1998 Nov-Dec;18(6):1205-11 – reference: 9925057 - Chest. 1999 Jan;115(1):12-8 – reference: 1938852 - J Assoc Physicians India. 1991 Jun;39(6):470-1 – reference: 3768246 - Br J Clin Pharmacol. 1986 Sep;22(3):343-5 – reference: 19432554 - Clin Infect Dis. 2009 Jun 15;48(12):1685-94 – reference: 6385429 - Tubercle. 1984 Sep;65(3):211-27 – reference: 10049268 - Antimicrob Agents Chemother. 1999 Mar;43(3):568-72 – reference: 18214560 - Eur J Clin Microbiol Infect Dis. 2008 Jun;27(6):467-72 – reference: 11713129 - Chest. 2001 Nov;120(5):1520-4 – reference: 9596291 - Chest. 1998 May;113(5):1178-83 – reference: 17452486 - Antimicrob Agents Chemother. 2007 Jul;51(7):2546-51 – reference: 14699462 - Clin Infect Dis. 2004 Jan 15;38(2):280-3 – reference: 16028152 - Clin Infect Dis. 2005 Aug 15;41(4):461-9 – reference: 9154882 - Am J Respir Crit Care Med. 1997 May;155(5):1717-22 – reference: 10460103 - Int J Tuberc Lung Dis. 1999 Aug;3(8):703-10 – reference: 9243044 - Clin Infect Dis. 1997 Jul;25(1):104-11 – reference: 22467672 - Clin Infect Dis. 2012 Jul;55(2):178-9 – reference: 19947806 - Pharmacotherapy. 2009 Dec;29(12):1468-81 – reference: 12531776 - Am J Respir Crit Care Med. 2003 May 15;167(10):1341-7 – reference: 16569826 - Antimicrob Agents Chemother. 2006 Apr;50(4):1170-7 – reference: 11499851 - Pharmacoepidemiol Drug Saf. 2001 Mar-Apr;10(2):127-34 – reference: 9265429 - Ann Intern Med. 1997 Aug 15;127(4):289-93 – reference: 6391781 - Clin Pharmacokinet. 1984 Nov-Dec;9(6):511-44 – reference: 7780091 - Tuber Lung Dis. 1995 Apr;76(2):109-13 – reference: 12381217 - Drugs. 2002;62(15):2169-83 – reference: 20550762 - Int J Tuberc Lung Dis. 2010 Jul;14(7):806-18 – reference: 22467670 - Clin Infect Dis. 2012 Jul;55(2):169-77 – reference: 6721995 - Br J Clin Pharmacol. 1984 Apr;17(4):481-4 – reference: 11170964 - Clin Infect Dis. 2001 Feb 1;32(3):515-7
SSID	ssj0006590
Score	2.332378
Snippet	East Africa has a high tuberculosis (TB) incidence and mortality, yet there are very limited data on exposure to TB drugs in patients from this region. We...
SourceID	proquest pubmed
SourceType	Aggregation Database Index Database
StartPage	3208
SubjectTerms	Adult Antitubercular Agents - blood Antitubercular Agents - pharmacokinetics Antitubercular Agents - therapeutic use Ethambutol - blood Ethambutol - pharmacokinetics Ethambutol - therapeutic use Female Humans Isoniazid - blood Isoniazid - pharmacokinetics Isoniazid - therapeutic use Male Pyrazinamide - blood Pyrazinamide - pharmacokinetics Pyrazinamide - therapeutic use Rifampin - blood Rifampin - pharmacokinetics Rifampin - therapeutic use Tanzania Treatment Outcome Tuberculosis, Pulmonary - drug therapy
Title	Pharmacokinetics of first-line tuberculosis drugs in Tanzanian patients
URI	https://www.ncbi.nlm.nih.gov/pubmed/23629715 https://www.proquest.com/docview/1367877195
Volume	57
WOSCitedRecordID	wos000320229600038&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText
inHoldings	1
isFullTextHit
isPrint
link	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3Pa9swFH6szVp66dZ0_bkNFUpO1VLbUqR3KqEs66EJOWSQW5BkuYQNu42TQf77PdkOORUKvRgbJDBPT-990pO-D-CacqZHKVKuM--4UDLIvKDlPkJlfSAsNxW7_qMajfR0iuNmw61sjlVuYmIVqNPChT3ybqAW00pFKO-eX3hQjQrV1UZCYwdaCUGZMDHVdMsW3pNYsxGg5vTe2xx8j3W337__QekegxbA6-CySjKDT-_9vc9w2MBL1q_94Qg--LwNe7Xg5LoN-8OmlN6GzrgmrV7fsMn2DlZ5wzpsvKWzXh_Dr83nH-oXmrAiY9mcUCMPEJUtV9Yv3OpvUc5Lli5WTyWb52xCmNPk5HusYW4tv8Dvwc_J_QNv5Be4IZC45NKkkTF4izSY2mkRWSWjXpYKZYVKnBWJ9-jScI9PJl7ZOE4VLVBUorQlIIPxCezmRe7PgKHFTFgVOVoMCmliwqQaM0PWihKHAs_hamPVGbl3qFmY3Bercra16zmc1kMze655OGYxJV9Ukbx4Q-9LOIgrIQsKqbdfoZXR5Pbf4KP7t5yXi--V39BzNB7-B3y9zIY
linkProvider	ProQuest
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Pharmacokinetics+of+first-line+tuberculosis+drugs+in+Tanzanian+patients&rft.jtitle=Antimicrobial+agents+and+chemotherapy&rft.au=Tostmann%2C+Alma&rft.au=Mtabho%2C+Charles+M&rft.au=Semvua%2C+Hadija+H&rft.au=van+den+Boogaard%2C+Jossy&rft.date=2013-07-01&rft.issn=1098-6596&rft.eissn=1098-6596&rft.volume=57&rft.issue=7&rft.spage=3208&rft_id=info:doi/10.1128%2FAAC.02599-12&rft.externalDBID=NO_FULL_TEXT
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1098-6596&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1098-6596&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1098-6596&client=summon